Boehringer Ingelheim

CompanyGermanyFounded 1885

ROROpenAlexWikidata

Boehringer Ingelheim develops 40 assets, the furthest approved, not sold in the US (Aggrenox). Mostly small molecule and antibody acting on PDE4B, PDE9A and SLC29A1; based in Germany, founded in 1885.

40
Assets
Furthest stage
Approved, not sold in the US
830
Trials
282
Signals

Pipeline

40
  • Aggrenox

    Fixed combination of aspirin and dipyridamole acting as antiplatelet agents

    Approved, not sold in the US, Small molecule, SLC29A1, PDE4B, stroke (Phase 3), coronary artery disease (Phase 3)

  • empagliflozin

    Inhibits renal SGLT2, increasing urinary glucose excretion and lowering blood glucose.

    Approved, Small molecule, SLC5A2, type 2 diabetes, heart failure

  • Hernexeos

    Inhibits HER2 signaling to suppress growth of HER2-driven cancer cells.

    Approved, Small molecule, ERBB2, metastatic non squamous non small cell lung cancer

37 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

2

In the full profile

  • Evidence behind the mechanisms12
  • Trials1,003
  • Deals1
  • Signals20
  • Integrity notices4
  • Similar companies6

Papers

Intelligence